Goldman Sachs Forecasts High Gas Prices And LNG Demand Drive Kinder Morgan's Revenue
Goldman Sachs analyst John Mackay reiterated a Buy rating on Thursday on the shares of Kinder Morgan Inc (NYSE:KMI) with a price forecast of $31.00.
The analyst anticipates first-quarter EBITDA of $2.18 billion, slightly above consensus estimates of $2.14 billion and company guidance of $2.17 billion.
Analysts project EBDA of $1.54 billion in the first-quarter, up from $1.43 billion in fourth-quarter FY24, driven by contributions from the Outrigger acquisition, higher natural gas prices, and seasonal marketing benefits.
Given stronger LNG demand and an improving gas macro environment, this quarter marks a shift where market fundamentals support execution, unlike 2024, when lower commodity prices posed challenges.
Also Read:
Kinder Morgan anticipates the first-quarter to benefit from higher commodity prices, marking a shift after four consecutive quarters of weaker-than-expected pricing in FY24.
While only 5% of KMI's business is directly impacted by commodity fluctuations, improved gas and crude pricing could provide a $50 million tailwind, partially offset by weaker D3 RIN prices, which may result in a $25 million headwind if trends persist.
Kinder sees substantial natural gas demand growth between 2024 and 2030, with LNG exports accounting for most of the projected increase.
While power sector growth and coal-to-gas switching contribute, LNG remains the dominant driver. KMI's 45-50% market share in LNG exports and power plant connections position it to capitalize on expansion, particularly in Texas, Louisiana, and the southern U.S.
The company is expected to shift its focus from large-scale projects to smaller sized developments in the coming months.
While 2024 saw billion-dollar projects like SSE4, MSX, and Trident, future announcements will likely range from hundreds of millions to $500 million.
Larger expansions, such as scaling up Trident's capacity, remain possibilities, with updates expected throughout 2025, noted the analyst.
Price Action: KMI shares traded lower by 0.30% at $28.15 at last check Friday.
Read Next:Image via Shutterstock.
Date
Firm
Action
From
To
Jan 2022
Wolfe Research
Upgrades
Underperform
Peer Perform
Jun 2021
Stifel
Downgrades
Buy
Hold
Jun 2021
Goldman Sachs
Downgrades
Neutral
Sell
View More Analyst Ratings for KMI
View the Latest Analyst Ratings
UNLOCKED: 5 NEW TRADES EVERY WEEK. Click now to get top trade ideas daily, plus unlimited access to cutting-edge tools and strategies to gain an edge in the markets.
Get the latest stock analysis from Benzinga?
KINDER MORGAN (KMI): Free Stock Analysis Report
This article Goldman Sachs Forecasts High Gas Prices And LNG Demand Drive Kinder Morgan's Revenue originally appeared on Benzinga.com
© 2025 Benzinga.com. Benzinga does not provide investment advice. All rights reserved.
Try Our AI Features
Explore what Daily8 AI can do for you:
Comments
No comments yet...
Related Articles
Yahoo
an hour ago
- Yahoo
Incyte (INCY) Targets $1B Growth by 2029 with New Drug Launches
Incyte Corporation (NASDAQ:INCY) is one of the 8 cheap beginner stocks to buy right now. At the 46th Annual Global Healthcare Conference hosted by Goldman Sachs on June 9, Incyte Corporation (NASDAQ:INCY) delivered a presentation, detailing its long-term strategic goals. The company highlighted its growing pipeline and expected revenue growth from new pharmaceutical launches while addressing the imminent loss of exclusivity for its main medicine, Jakafi. In Q1 2025, Jakafi grew 24% year-over-year. According to management, three factors contributed to this growth. 10% came from demand, 7% from net pricing, and 7% from less destocking this year than in the same quarter last year. Looking ahead, Incyte Corporation (NASDAQ:INCY) anticipates that demand will be the only factor driving growth for the remainder of the year. To broaden its portfolio beyond Jakafi, however, the company intends to introduce four new products or indications in 2025, with the goal of generating an extra $1 billion in revenue by 2029. Incyte Corporation (NASDAQ:INCY), an American global pharmaceutical company, operates as a market leader in developing treatments for patients suffering from various diseases, including cancer. While we acknowledge the potential of INCY as an investment, we believe certain AI stocks offer greater upside potential and carry less downside risk. If you're looking for an extremely undervalued AI stock that also stands to benefit significantly from Trump-era tariffs and the onshoring trend, see our free report on the best short-term AI stock. Read More: and Disclosure: None. Error in retrieving data Sign in to access your portfolio Error in retrieving data Error in retrieving data Error in retrieving data Error in retrieving data
Yahoo
2 hours ago
- Yahoo
Jim Cramer Notes Rockwell Automation is 'Going in the Right Direction'
Rockwell Automation, Inc. (NYSE:ROK) is one of the 16 stocks Jim Cramer recently discussed. The company was discussed during the episode, and here's what Mad Money's host had to say: 'So if you want a manufacturer, you know what you gotta do? You gotta embrace automation, which brings me to Rockwell Automation, the leading industrial automation, digital transformation company. Now these guys make equipment and software that allows factories to run with fewer workers. That's exactly what we're going to need if we're going to have domestic manufacturing make a comeback… Crucially, when the company reported that last quarter, about a month ago, Rockwell maintained its full-year sales outlook, and it raised its full-year earnings forecast really significantly. A technician in a factory setting next to an industrial automation machine. Rockwell Automation (NYSE:ROK) delivers industrial automation and digital transformation products. The company provides hardware, software, and services such as control, safety, motion, sensing equipment, consulting, and maintenance. While we acknowledge the potential of ROK as an investment, we believe certain AI stocks offer greater upside potential and carry less downside risk. If you're looking for an extremely undervalued AI stock that also stands to benefit significantly from Trump-era tariffs and the onshoring trend, see our free report on the best short-term AI stock. READ NEXT: The Best and Worst Dow Stocks for the Next 12 Months and 10 Unstoppable Stocks That Could Double Your Money. Disclosure: None. Error in retrieving data Sign in to access your portfolio Error in retrieving data Error in retrieving data Error in retrieving data Error in retrieving data
Yahoo
2 hours ago
- Yahoo
Jim Cramer on Goldman Sachs: 'There's a Thirst That Can't Be Slaked Without More Deals'
The Goldman Sachs Group, Inc. (NYSE:GS) is one of the 16 stocks Jim Cramer recently discussed. Cramer noted that investors who are interested in investing in IPOs can go for GS stock, as he explained: 'I've tried to be skeptical of these three red hot areas, but as I told you last week, once the thing really takes off, you can't be a scold. I'm not about you not making money, I'm about you making money. And the market's saying, listen, these companies can raise some money, and I think you're going to see scores more coming public. By the way, we own Goldman Sachs for the Charitable Trust; that's another way to play it. The investment banks are eager to give it to them, and they know that there's a thirst that can't be slaked without more deals.' A close-up of a financial advisor giving advice to a customer, demonstrating the importance of consumer and wealth management. Goldman Sachs (NYSE:GS) is a financial firm that provides wealth management and various financial solutions. While we acknowledge the potential of GS as an investment, we believe certain AI stocks offer greater upside potential and carry less downside risk. If you're looking for an extremely undervalued AI stock that also stands to benefit significantly from Trump-era tariffs and the onshoring trend, see our free report on the best short-term AI stock. READ NEXT: The Best and Worst Dow Stocks for the Next 12 Months and 10 Unstoppable Stocks That Could Double Your Money. Disclosure: None. Error in retrieving data Sign in to access your portfolio Error in retrieving data Error in retrieving data Error in retrieving data Error in retrieving data
